ArticleJHEP reports : innovation in hepatology2026
Glycodeoxycholic acid inhibits hepatocellular carcinoma by driving M1 polarization of macrophages via the S1PR2-NF-κB-NLRP3 pathway.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsAs liver-specific metabolites, bile acids could regulate antitumor immune responses and could represent a new therapeutic strategy for hepatocellular carcinoma (HCC).
methodsThis study integrated metabolomics, transcriptomics, and immunofluorescence of clinical tissues (61 paired tumor and adjacent samples) and peripheral blood (serum from 59 patients with HCC and 19 healthy individuals) to identify differential bile acids and explore their correlations with clinicopathological features and immunity in HCC. Focusing on the identified bile acid glycodeoxycholic acid (GDCA), we elucidated its regulatory mechanisms in the tumor microenvironment (TME), especially M1 polarization of macrophages, and its roles in inhibiting HCC progression and enhancing the efficacy of immunotherapy.
resultsGDCA was significantly reduced (p = 0.0026) in HCC tissues and was closely associated with adverse clinicopathological features, such as vascular invasion (p = 0.029) and advanced TNM stages (p = 0.014), as well as an immunosuppressive TME. Mechanistic studies revealed that GDCA activated M1 macrophages through the S1PR2-NF-κB-NLRP3 pathway, exerting antitumor immune effects. It could also synergize with anti-PD-1 antibodies to enhance anti-HCC efficacy.
conclusionsThis study showed that the bile acid GDCA inhibited HCC progression by driving M1 macrophage polarization, suggesting targeting bile acids to reshape the tumor immune microenvironment as a viable strategy to enhance therapy. IMPACT AND IMPLICATIONS: A specific bile acid, GDCA, is significantly reduced in liver cancer (HCC) tissue, with lower GDCA levels associating with adverse clinicopathological features and a weaker antitumor immune response. This study found that GDCA can reprogram tumor-associated macrophages into a tumor-fighting state by activating a specific molecular pathway (S1PR2-NF-κB-NLRP3). In animal models, restoring GDCA levels inhibited tumor growth and worked synergistically with anti-PD-1 immunotherapy. These findings reveal a new mechanism of immune regulation in HCC and suggest targeting bile acid metabolism as a promising strategy to enhance immunotherapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.